Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has shared an update.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. held its 2025 first extraordinary general meeting where key resolutions were passed, including the abolition of the supervisory committee and amendments to the company’s articles of association and governance measures. The election of Mr. Pu Hong as an independent non-executive director was also approved, reflecting the company’s efforts to streamline governance and enhance its board’s independence.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of heparin and related products. The company is based in China and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 1,034,778
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.14B
See more insights into 9989 stock on TipRanks’ Stock Analysis page.